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Reviewed by Nathan Nobis,Morehouse College and Morehouse School of Medicine
In 2005 the Food and Drug Administration (FDA)
approved the drug BiDil, a combination of two generic
vasodilators (hence bi-dil), with specific indication to treat
heart failure in black patients. The drug was approved
largely on the basis of results from a small clinical trial of
only self-identified black patients.
Obviously, however, if a drug works with a particular
population, that gives no indication that drug will work
only with that population or have unique benefits solely
for that population: The drug might work for anyone, of
any population, and so works well for a subpopulation. So
there is some mystery why BiDil was approved, with this
specific indication, on this basis. In Race in a Bottle: The
Story of BiDil and Racialized Medicine in the Post-Genomic
Age, law professor and historian Jonathan Kahn investi-
gates this mystery.
BiDil’s developers argued that there must be some
latent genetic explanation for the drug’s success with black
patients—this argument underlies their claim that BiDil
uniquely benefits black people. They suggest that race
serves as useful surrogate or proxy until further genetic
information is revealed.
A major goal of the book is to rebut this explanation.
Kahn argues that, according to the best science (and phil-
osophical theorizing about the nature of races), there is
no genetic basis for race: There are no unique genes that
classify (those who many see as) white people as white
and (those who many see as) black people as black, and
so on. Race-specific efficacy in drugs is therefore unlikely
and dubious, given the lack of race-specific biological
mechanisms needed for these drugs to perform as
promised.
What role should race play in medicine and public
health, then? While Kahn provides positive proposals
here, another of his major goals is to argue that race-spe-
cific drugs have the (typically unintended) negative conse-
quence of undermining potentially effective projects to
address racial health disparities. If we believe that health
inequalities are, at root, an unfortunate consequence of
genetics and biology—and not a consequence of unfair
social, political, and educational opportunities, environ-
mental quality, inequalities in health care access, racism in
health care, and other social causes—then there is little rea-
son to focus on these very challenging and demanding
issues of justice and the distribution of health-related
social, educational, and vocational goods: Just take a pill!
But if the pills don’t work, and they lead us to ignore or
downplay strategies that will work, then the drugs wrong-
fully distract—to the detriment of those the drugs were
developed to benefit.
In what follows, I briefly summarize the book’s intro-
duction, eight chapters, and very helpful “Conclusions
and Recommendations,” and comment on some of the
main issues of each chapter.
In the introduction, Kahn briefly reviews scientific evi-
dence that race is not genetic, noting, “There is no genetic
basis for marking off where one race ends and another
begins” (3). To be of a particular race is not to have any
particular biological-kind-creating genes or biological
makeup, and so, Kahn argues, any race-specific drug (that
works even better with particular races) is unlikely, as are
race-specific medical conditions. For example, sickle cell
anemia isn’t, as many people think, a “black” disease, but
results from a trait common to many descendants from
areas with high malaria rates, irrespective of race (13).
And while African-Americans as a group have high rates
of hypertension, Africans in Nigeria have very low rates of
hypertension (13). Kahn later reports that the drug warfa-
rin is better dosed directly on the basis of an individual
patient’s own genes, rather than indirectly on the basis of
the patient’s racial group. Thus, Kahn gives theoretical
and empirical reasons to reject race as a biological cate-
gory, along with any practices that depend on this false
biological assumption. (For further discussion of the
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Kahn presents race as “a complex and dynamic social
construct” (2). A concern throughout the book is legitimate
and illegitimate uses of racial concepts, on medical, scien-
tific, legal, social, and moral grounds.
Given the dubious connections between race and
genetics, why do scientists and health professionals con-
tinue to write and research as if race is a biological reality?
In Chapter 1, “Organizing Race,” Kahn reports that there
are many federal and other regulatory requirements to
report on and categorize research data by race. Researchers
must meet these requirements, but often they do this in
ways that are not very careful or precise: Kahn offers
revealing quotes from researchers expressing puzzlement
about what races are and candid admissions that they do
not really understand what races are (44–45). Nevertheless,
regulatory requirements and incentives force “the intro-
duction of race into contemporary biomedicine” (47). If
this concept is misunderstood and misused, the potential
for harm is great.
Chapter 2 describes the “birth” of BiDil in the 1980s. In
1999 the drug company NitroMed bought the BiDil patent,
which was set to expire in 2007. The drug, a combination
of two generic drugs, had been used for more than a
decade to treat heart failure in patients irrespective of race.
NitroMed sought a race-specific patent to remarket the
same drug, but with a new specific indication for black
patients. The FDA granted the patent in 2005, and this sec-
ond patent lasts until 2020. Kahn argues that commercial,
that is, financial, interests led the way for seeking this pat-
ent protection, not any strong medical or scientific evi-
dence that BiDil was uniquely helpful for black patients;
indeed, he has testified to this effect before the FDA (94–
95). The extensive details of Kahn’s case for why, ulti-
mately, there was no good scientific evidence to support a
race-specific indication for a generally useful drug are
worth reviewing.
Chapter 3, “Statistical Mischief and Racial Frames of
Drug Development and Marketing,” argues that a com-
mon statistic, that “death rates from heart failure are more
than twice as high in black patients than in white patients”
(71) is false—very false, since the correct statistic is under
1.1 to 1 (72). Nevertheless, this false statistic took on a life
of its own and provided the context for a perceived “need”
for a drug like BiDil. Yet such statistics do not support the
dubious theory that there is a biological or genetic explana-
tion for the racial health disparity: The causes may be
social, environmental, and/or related to health care access
and many other potential causes.
In Chapter 4, “Capitalizing [on] Race in Drug Devel-
opment,” Kahn argues that “BiDil was not about personal-
izing medicine; it was about exploiting race to obtain
cheaper, quicker FDA approval for a drug” (88). He
discusses some of the promises and pitfalls of
pharmacogenomics, and dangers in using race as a proxy
or surrogate for individual genetic markers relevant to a
medical condition. Most interestingly, this chapter reports
that, despite all the initial excitement about BiDil, the drug
ultimately was a financial failure: It was not widely pre-
scribed for a variety of reasons, including many phys-
icians’ skepticism about race-specific therapies, and a
sense that the two generic, inexpensive vasodilators
worked just as well (a view that NitroMed tried to rebut).
Chapter 5, “Race-ing Patents/Patenting Race,”
explores race-focused drug patents. Kahn argues that this
phenomenon, too, reinforces the false understanding of
race in terms of genetics and opens the door to racial and
genetic discrimination of various kinds.
Chapter 6, “Not Fade Away,” explores the common
insistence that at present race is the best surrogate we have
for genetics, but that racial identification for medical pur-
poses will eventually “fade away” when we have better
genetic information. Kahn observes that there are unfortu-
nate incentives and motivations to keep racial categories in
drug development, even when they should be eliminated.
In Chapter 7, “From Disparity to Difference,” Kahn
argues that “geneticizing health disparities . . . has power-
ful implications . . . for how we address the historical lega-
cies of racial injustice in this country” (223). Seeing health
disparities as primarily genetic undercuts the need to
address social, educational, and political inequalities on
racial lines; addressing disparities becomes more of a pri-
vate, individual matter, and less a matter of social justice.
Kahn observes that this message supports (and is sup-
ported by) some financial and political agendas, but does
not help those who suffer due to health inequalities.
Finally, in a “Conclusion and Recommendations” sec-
tion, Kahn urges for far greater rigor, precision, and care in
using race designations in research and law, especially
concerning whether “race” is meant as a social group or a
biological designation.
In conclusion, Kahn’s book very is important and well
worth studying, as it addresses profound issues of racial
justice concerning health care and health-related research
(and health and well-being in general). The book was
developed out of 20 or so of Kahn’s academic writings on
the topics, mostly in medical and law journals; the most
“popular” source was an article by him in Scientific Ameri-
can. Given the importance of these issues and their need to
be widely understood and discussed, even by those with-
out medical and legal backgrounds, I urge Kahn to
develop a more “popular” and accessible account of BiDil
and his arguments concerning social justice and race, med-
icine, and health care. Doing so would surely contribute to
the justice and equality that we seek. &
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